Articles

The Importance of Clinical Trials for Genitourinary Malignancies - Evan Yu and Sumanta Kumar Pal

As we counsel our patients about the importance of clinical research, there are two key messages to send. The first is that without clinical trials, we would not have access to the large number of life-prolonging therapies that we have for genitourinary cancers and others. That translates into more family trips, birthday parties, time spent with grandchildren and graduations attended. It translates into more time spent being productive at work, and net increase into societal wealth. These have meaningful impact. The second is that enrolling on a clinical trial is largely about altruism. The typical patient wants to receive a therapy that will help him/her. That is reasonable; however, the greatest reason to enroll in a clinical trial is that new knowledge will be gained regardless of the outcome.

Sequencing and Combining CRPC Therapies - What Does the Future Hold? – Charles Ryan

The European Association of Urology defines castration-resistant prostate cancer (CRPC) as serum testosterone < 50 ng/dL or < 1.7 nmol/L plus either biochemical progression (three consecutive rises in prostate-specific antigen [PSA] one week apart, resulting in two 50% increases over the nadir, and PSA > 2 ng/mL) or radiologic progression (at least two new bone scan lesions or a soft tissue lesion using Response Evaluation Criteria in Solid Tumors [RECIST]).¹ Symptomatic progression alone is not enough to diagnose CRPC; instead, it should trigger further investigation.

Chemotherapy in Prostate Cancer- When, Why and How - Fred Saad

Until 2010, our treatment armamentarium for prostate cancer (PC) was fairly limited. Patients received local therapy for non-metastatic disease, androgen deprivation therapy (ADT) for hormone-naïve metastatic disease, denosumab and zoledronic acid for metastatic castration-resistant prostate cancer (mCRPC), and bisphosphonates or docetaxel for symptomatic mCRPC.

A Review On The Development of Targeted Alpha Therapy in the Treatment of Cancer: EVERYDAY UROLOGY-Full Text Article

Everyday Urology-Oncology Insights: Volume 2, Issue 2

Focusing on The First and Only FDA Approved Targeted Alpha Therapy Radium-223 in the Treatment of mCRPC

INTRODUCTION
The Tenth Symposium on Targeted Alpha Therapy (TAT-10) opened on Wednesday, May 31, 2017 in Kanazawa Japan. The symposium was jointly organized by the Joint Research Centre (JRC) of the European Commission and Kanazawa University as a forum for presentations on the latest developments in radiotherapy with alpha emitters in cancer. With over 200 participants the symposium covered advances in cancer treatment using alpha emitters as targeted therapy, clinical and preclinical research, radionuclide production, instrumentation and dosimetry.¹

The Multidisciplinary Approach to Prostate Cancer Management: From Diagnosis and Beyond: EVERYDAY UROLOGY- Full Text Article

Everyday Urology-Oncology Insights: Volume 2, Issue 2

When patients receive a diagnosis of cancer it can be devastating. Suddenly their world is turned upside down, populated by doctors, diagnostic tests, and treatments.

Assessment of Cardiovascular Risk With the Use of Androgen Deprivation Therapy for Prostate Cancer: EVERYDAY UROLOGY- Full Text Article

Everyday Urology-Oncology Insights: Volume 2, Issue 1

Heart disease and cancer are the leading causes of death in the United States.¹ Prostate cancer (PC) is the most common cancer in American men, and PC is most frequently diagnosed among men aged 65 to 74 years.² The American Cancer Society’s estimates for PC in the United States for 2017 are about 161,360 new cases. Of these, about 26,730 are expected to die of the disease.¹

Enhanced Recovery After Surgery, Radical Cystectomy and Urinary Diversion: EVERYDAY UROLOGY-Full Text Article

Everyday Urology-Oncology Insights: Volume 2, Issue 1

Bladder cancer presents an ever increasing health care burden across the globe. The large majority of patients diagnosed with bladder cancer are over the age of 55, with an average age at the time of diagnosis of 73 and an increasing percentage 80 years and older.¹ Men are about three to four times more likely to get bladder cancer during their lifetime than women.¹

Page 1 of 3

Login